These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 32473642)

  • 1. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19.
    Sharun K; Dhama K; Patel SK; Pathak M; Tiwari R; Singh BR; Sah R; Bonilla-Aldana DK; Rodriguez-Morales AJ; Leblebicioglu H
    Ann Clin Microbiol Antimicrob; 2020 May; 19(1):23. PubMed ID: 32473642
    [No Abstract]   [Full Text] [Related]  

  • 2. Ivermectin and COVID-19: Keeping Rigor in Times of Urgency.
    Chaccour C; Hammann F; Ramón-García S; Rabinovich NR
    Am J Trop Med Hyg; 2020 Jun; 102(6):1156-1157. PubMed ID: 32314704
    [No Abstract]   [Full Text] [Related]  

  • 3. Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses.
    Bray M; Rayner C; Noël F; Jans D; Wagstaff K
    Antiviral Res; 2020 Jun; 178():104805. PubMed ID: 32330482
    [No Abstract]   [Full Text] [Related]  

  • 4. Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection.
    Liu Z; Xia S; Wang X; Lan Q; Xu W; Wang Q; Jiang S; Lu L
    Virol Sin; 2020 Jun; 35(3):340-343. PubMed ID: 32236815
    [No Abstract]   [Full Text] [Related]  

  • 5. Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19).
    Al-Tawfiq JA
    Travel Med Infect Dis; 2020; 35():101608. PubMed ID: 32114075
    [No Abstract]   [Full Text] [Related]  

  • 6. Diagnosis and Management of First Case of COVID-19 in Canada: Lessons Applied From SARS-CoV-1.
    Marchand-Senécal X; Kozak R; Mubareka S; Salt N; Gubbay JB; Eshaghi A; Allen V; Li Y; Bastien N; Gilmour M; Ozaldin O; Leis JA
    Clin Infect Dis; 2020 Nov; 71(16):2207-2210. PubMed ID: 32147731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to "Quantitative Clinical Pharmacology INPUT to SARS-CoV-2 Therapeutics Should be Based on Robust Data".
    Garcia-Cremades M; Solans BP; Hughes E; Ernest JP; Wallender E; Savic RM
    Clin Pharmacol Ther; 2020 Aug; 108(2):189. PubMed ID: 32348544
    [No Abstract]   [Full Text] [Related]  

  • 8. From SARS-CoV to SARS-CoV-2: The response and challenge of forensic infectious disease autopsy.
    Wang HJ
    Fa Yi Xue Za Zhi; 2020 Feb; 36(1):1-3. PubMed ID: 32198983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cluster of pneumonia associated with the SARS-Cov-2 outside of Wuhan related to a house-warming banquet.
    Liu L; Quan J; Lv J; Long S; Hu W; Zhuge H; Zhou Z; Zhao D
    J Infect; 2020 Jul; 81(1):147-178. PubMed ID: 32283138
    [No Abstract]   [Full Text] [Related]  

  • 10. Pangolins Harbor SARS-CoV-2-Related Coronaviruses.
    Han GZ
    Trends Microbiol; 2020 Jul; 28(7):515-517. PubMed ID: 32544437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of SARS-CoV-2 viral RNA in asymptomatic carriers.
    Yan X; Han X; Fan Y; Fang Z; Long D; Zhu Y
    Crit Care; 2020 May; 24(1):245. PubMed ID: 32448332
    [No Abstract]   [Full Text] [Related]  

  • 12. Duration for carrying SARS-CoV-2 in COVID-19 patients.
    Du X; Yu X; Li Q; Li X; Qin T; Luo Q; Wang M; Jiang M; Bai L; Wang X; Pan Y
    J Infect; 2020 Jul; 81(1):e78-e79. PubMed ID: 32283161
    [No Abstract]   [Full Text] [Related]  

  • 13. Challenges and issues of SARS-CoV-2 pool testing.
    Eberhardt JN; Breuckmann NP; Eberhardt CS
    Lancet Infect Dis; 2020 Nov; 20(11):1233-1234. PubMed ID: 32679088
    [No Abstract]   [Full Text] [Related]  

  • 14. Challenges and issues of SARS-CoV-2 pool testing.
    Mishra B; Behera B; Mohanty M; Ravindra A; Ranjan J
    Lancet Infect Dis; 2020 Nov; 20(11):1233. PubMed ID: 32679083
    [No Abstract]   [Full Text] [Related]  

  • 15. Challenges and issues of SARS-CoV-2 pool testing.
    Lee J; Kim SY; Sung H; Lee SW; Lee H; Roh KH; Yoo CK; Hong KH
    Lancet Infect Dis; 2020 Nov; 20(11):1232-1233. PubMed ID: 32679080
    [No Abstract]   [Full Text] [Related]  

  • 16. Why Does SARS-CoV-2 Invade the Gastrointestinal Epithelium?
    Uno Y
    Gastroenterology; 2020 Oct; 159(4):1622-1623. PubMed ID: 32283099
    [No Abstract]   [Full Text] [Related]  

  • 17. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The index case of SARS-CoV-2 in Scotland.
    Hill KJ; Russell CD; Clifford S; Templeton K; Mackintosh CL; Koch O; Sutherland RK
    J Infect; 2020 Jul; 81(1):147-178. PubMed ID: 32205138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV, Mers-CoV and COVID-19: what differences from a dermatological viewpoint?
    Rongioletti F
    J Eur Acad Dermatol Venereol; 2020 Oct; 34(10):e581-e582. PubMed ID: 32526085
    [No Abstract]   [Full Text] [Related]  

  • 20. Authors' response: Plenty of coronaviruses but no SARS-CoV-2.
    Reusken CB; Haagmans B; Meijer A; Corman VM; Papa A; Charrel R; Drosten C; Koopmans M
    Euro Surveill; 2020 Feb; 25(8):. PubMed ID: 32127125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 37.